-
Share
21,923 Posts.
899
06/05/20
14:14
Share
Pathetictrader
IMO
Do you realise the SNO poster data released in November was for less than 10 patients. - still very speculative imo
Surely you cant expect the market to reward shareholders without data on hundreds of varying degrees of patients
Good results on Phase 11 or 111 on hundreds of patients is usually rewarded
Who has Control over trials and extent should be an area of research imo
DYOR
-
